KEVZARA

KEVZARA- sarilumab injection, solution
sanofi-aventis U.S. LLC

WARNING: RISK OF SERIOUS INFECTIONS

Patients treated with KEVZARA are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions (5.1), Adverse Reactions (6.1)]. Opportunistic infections have also been reported in patients receiving KEVZARA. Most patients who developed infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.

Avoid use of KEVZARA in patients with an active infection.

Reported infections include:

  • Active tuberculosis, which may present with pulmonary or extrapulmonary disease. Patients should be tested for latent tuberculosis before KEVZARA use and during therapy. Treatment for latent infection should be initiated prior to KEVZARA use.
  • Invasive fungal infections, such as candidiasis, and pneumocystis. Patients with invasive fungal infections may present with disseminated, rather than localized, disease.
  • Bacterial, viral and other infections due to opportunistic pathogens.

Closely monitor patients for signs and symptoms of infection during treatment with KEVZARA. If a serious infection develops, interrupt KEVZARA until the infection is controlled.

Consider the risks and benefits of treatment with KEVZARA prior to initiating therapy in patients with chronic or recurrent infection.

1 INDICATIONS AND USAGE

1.1 Rheumatoid Arthritis (RA)

KEVZARA® is indicated for treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs).

1.2 Polymyalgia Rheumatica (PMR)

KEVZARA is indicated for treatment of adult patients with polymyalgia rheumatica who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper.

2 DOSAGE AND ADMINISTRATION

2.1 General Considerations Prior to Administration

Not Recommended for Concomitant Use with Biological DMARDS

The concurrent use of KEVZARA with biological DMARDs such as TNF antagonists, IL-1R antagonists, anti-CD20 monoclonal antibodies and selective co-stimulation modulators has not been studied. Avoid using KEVZARA with biological DMARDs because of the possibility of increased immunosuppression and increased risk of infection.

Recommended Evaluations Prior to Treatment

  • Complete blood count (CBC): Treatment initiation with KEVZARA is not recommended in patients with an absolute neutrophil count (ANC) below 2000 per mm3 , or platelet count below 150,000 per mm3. Monitor laboratory parameters [see Warnings and Precautions (5.2)].
  • Liver function tests (LFT): Treatment initiation with KEVZARA is not recommended in patients with or who have alanine transaminase (ALT) or aspartate aminotransferase (AST) above 1.5 times the upper limit of normal (ULN). Monitor laboratory parameters [see Dosage and Administration (2.5) and Warnings and Precautions (5.2)].
  • Lipid parameters (total cholesterol, LDL cholesterol, HDL cholesterol and/or triglycerides): Assess lipid parameters at baseline. Monitor laboratory parameters [see Warnings and Precautions (5.2)].
  • Active and latent tuberculosis infection evaluation: Prior to initiating KEVZARA, test patients for active and latent tuberculosis (TB). KEVZARA should not be administered to patients with active TB. If positive for latent infection, consider treating for TB prior to KEVZARA use [see Warnings and Precautions (5.1)].
  • Evaluate for infections: Avoid KEVZARA use in patients with active infections [see Warnings and Precautions (5.1)].

2.2 Recommended Dosage for Rheumatoid Arthritis

The recommended dosage of KEVZARA is 200 mg once every two weeks given as a subcutaneous injection (see Dosage and Administration 2.1).

KEVZARA may be used as monotherapy or in combination with methotrexate (MTX) or other conventional DMARDs.

Modify the dosage as recommended in Table 1 if the patient develops neutropenia, thrombocytopenia, or liver enzyme abnormalities [see Dosage and Administration (2.5), Warnings and Precautions (5.2) and Adverse Reactions (6.1)].

2.3 Recommended Dosage for Polymyalgia Rheumatica

The recommended dosage of KEVZARA is 200 mg once every two weeks given as a subcutaneous injection, in combination with a tapering course of systemic corticosteroids [see Dosage and Administration (2.1)]. KEVZARA can be used as monotherapy following discontinuation of corticosteroids.

Discontinue KEVZARA if the patient develops neutropenia (using ANC results obtained at the end of the dosing interval), thrombocytopenia, or liver enzyme abnormalities [see Dosage and Administration (2.5), Warnings and Precautions (5.2) and Adverse Reactions (6.1)].

2.4 Preparation and Administration Instructions

  • KEVZARA is intended for use under the guidance of a healthcare professional. A patient may self-inject KEVZARA or the patient’s caregiver may administer KEVZARA. Provide proper training to patients and/or caregivers on the preparation and administration of KEVZARA prior to use according to the Instructions for Use (IFU).
  • Allow the pre-filled syringe to sit at room temperature for 30 minutes prior to subcutaneous injection. Do not warm KEVZARA in any other way.
  • If using a pre-filled pen, allow the pre-filled pen to sit at room temperature for 60 minutes prior to subcutaneous injection. Do not warm KEVZARA in any other way.
  • Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. KEVZARA solution should be clear and colorless to pale yellow. Do not use if the solution is cloudy, discolored or contains particles, or if any part of the pre-filled syringe or pre-filled pen appears to be damaged.
  • Instruct patients to inject the full amount in the syringe or pen (1.14 mL), which provides 200 mg or 150 mg of KEVZARA, according to the directions provided in the IFU.
  • Rotate injection sites with each injection. Do not inject into skin that is tender, damaged, or has bruises or scars.

2.5 Dosage Modifications for Cytopenias, Abnormal Liver Enzymes, or Infections

Dosage Modifications for Patients with Rheumatoid Arthritis

Table 1: Dosage Modifications due to Neutropenia, Thrombocytopenia, or Elevated Liver Enzymes in Patients with Rheumatoid Arthritis
Low Absolute Neutrophil Count (ANC)
Lab Value (cells/mm3) Recommendation
ANC greater than 1,000 Maintain current dosage of KEVZARA.
ANC 500 to 1,000 Hold treatment with KEVZARA until ANC greater than 1,000.KEVZARA can then be resumed at 150 mg every two weeks and increased to 200 mg every two weeks as clinically appropriate.
ANC less than 500 Discontinue KEVZARA.
Low Platelet Count
Lab Value (cells/mm3) Recommendation
50,000 to 100,000 Hold treatment with KEVZARA until platelets greater than 100,000.KEVZARA can then be resumed at 150 mg every two weeks and increased to 200 mg every two weeks as clinically appropriate.
Less than 50,000 If confirmed by repeat testing, discontinue KEVZARA.
Liver Enzyme Abnormalities
Lab Value Recommendation
ALT or AST greater than ULN to 3 times ULN Consider dosage modification of concomitant DMARDs as clinically appropriate.
ALT or AST greater than 3 times ULN to 5 times ULN Hold treatment with KEVZARA until ALT or AST less than 3 times ULN.KEVZARA can then be resumed at 150 mg every two weeks and increased to 200 mg every two weeks as clinically appropriate.
ALT or AST greater than 5 times ULN Discontinue KEVZARA.
  • Infections: If a patient with RA develops a serious infection or an opportunistic infection, hold treatment with KEVZARA until the infection is controlled [see Warnings and Precautions (5.1)].

Dosage Modifications for Patients with Polymyalgia Rheumatica

  • Laboratory Abnormalities: Discontinue KEVZARA in patients with PMR who develop the following laboratory abnormalities [see Warnings and Precautions (5.2) and Clinical Pharmacology (12.2)]:
    • neutropenia (ANC below 1,000 per mm3 at the end of the dosing interval)
    • thrombocytopenia (platelet count below 100,000 per mm3)
    • AST or ALT elevations 3 times above the ULN
    Dosage modifications have not been studied in patients with PMR with these conditions. For treatment initiation criteria, refer to the dosage recommendations for PMR [see Dosage and Administration (2.1, 2.3)].
  • Infections: If a patient with PMR develops a serious infection or an opportunistic infection, hold treatment with KEVZARA until the infection is controlled [see Warnings and Precautions (5.1)].

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2023. All Rights Reserved.